Logo image of VIRX

VIRACTA THERAPEUTICS INC (VIRX) Stock Fundamental Analysis

NASDAQ:VIRX - Nasdaq - US92765F1084 - Common Stock - Currency: USD

0.0778  -0.07 (-48.65%)

After market: 0.071 -0.01 (-8.74%)

Fundamental Rating

0

VIRX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. VIRX has a bad profitability rating. Also its financial health evaluation is rather negative. VIRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VIRX has reported negative net income.
In the past year VIRX has reported a negative cash flow from operations.
VIRX had negative earnings in each of the past 5 years.
VIRX had a negative operating cash flow in each of the past 5 years.
VIRX Yearly Net Income VS EBIT VS OCF VS FCFVIRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -197.14%, VIRX is not doing good in the industry: 90.27% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -197.14%
ROE N/A
ROIC N/A
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
VIRX Yearly ROA, ROE, ROICVIRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VIRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIRX Yearly Profit, Operating, Gross MarginsVIRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, VIRX has more shares outstanding
VIRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VIRX has a worse debt to assets ratio.
VIRX Yearly Shares OutstandingVIRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
VIRX Yearly Total Debt VS Total AssetsVIRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

VIRX has an Altman-Z score of -26.24. This is a bad value and indicates that VIRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -26.24, VIRX is not doing good in the industry: 89.91% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.24
ROIC/WACCN/A
WACCN/A
VIRX Yearly LT Debt VS Equity VS FCFVIRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.76 indicates that VIRX may have some problems paying its short term obligations.
With a Current ratio value of 0.76, VIRX is not doing good in the industry: 91.33% of the companies in the same industry are doing better.
VIRX has a Quick Ratio of 0.76. This is a bad value and indicates that VIRX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of VIRX (0.76) is worse than 91.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.76
VIRX Yearly Current Assets VS Current LiabilitesVIRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.29% over the past year.
EPS 1Y (TTM)11.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.15% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.18%
EPS Next 2Y31.22%
EPS Next 3Y19.14%
EPS Next 5Y14.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIRX Yearly Revenue VS EstimatesVIRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
VIRX Yearly EPS VS EstimatesVIRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIRX Price Earnings VS Forward Price EarningsVIRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIRX Per share dataVIRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

VIRX's earnings are expected to grow with 19.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.22%
EPS Next 3Y19.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VIRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRACTA THERAPEUTICS INC

NASDAQ:VIRX (2/3/2025, 8:01:34 PM)

After market: 0.071 -0.01 (-8.74%)

0.0778

-0.07 (-48.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-05 2025-03-05/amc
Inst Owners48.83%
Inst Owner Change-33.41%
Ins Owners2.41%
Ins Owner Change0.52%
Market Cap3.09M
Analysts43.33
Price Target3.06 (3833.16%)
Short Float %0.06%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.86%
Min EPS beat(2)-8.04%
Max EPS beat(2)33.76%
EPS beat(4)2
Avg EPS beat(4)12.76%
Min EPS beat(4)-10.69%
Max EPS beat(4)36.03%
EPS beat(8)3
Avg EPS beat(8)8.46%
EPS beat(12)6
Avg EPS beat(12)5.61%
EPS beat(16)8
Avg EPS beat(16)20.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)56.18%
EPS NY rev (1m)0%
EPS NY rev (3m)8.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -197.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.76
Altman-Z -26.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y38.18%
EPS Next 2Y31.22%
EPS Next 3Y19.14%
EPS Next 5Y14.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.09%
OCF growth 3YN/A
OCF growth 5YN/A